Femasys Past Earnings Performance

Past criteria checks 0/6

Femasys's earnings have been declining at an average annual rate of -15.8%, while the Medical Equipment industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 0.1% per year.

Key information

-15.8%

Earnings growth rate

86.8%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-0.1%
Return on equity-77.6%
Net Margin-1,329.1%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Apr 03
Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Sep 27
Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Femasys commercially launches Femcerv for cervical cancer screening

Sep 29

Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M

Aug 10

We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

May 22
We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

Femasys: Revolutionizing Female Reproduction

Jul 16

Revenue & Expenses Breakdown
Beta

How Femasys makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:FEMY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231-1487
30 Sep 231-1376
30 Jun 231-1266
31 Mar 231-1166
31 Dec 221-1166
30 Sep 221-1166
30 Jun 221-1055
31 Mar 221-955
31 Dec 211-844
30 Sep 211-744
30 Jun 211-634
31 Mar 211-734
31 Dec 201-734
31 Dec 191-1157

Quality Earnings: FEMY is currently unprofitable.

Growing Profit Margin: FEMY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FEMY is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.

Accelerating Growth: Unable to compare FEMY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FEMY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).


Return on Equity

High ROE: FEMY has a negative Return on Equity (-77.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.